An interventional study of Follitropin Beta;MSD and Ganirelix in Infertility, sponsored by Reproductive & Genetic Hospital of CITIC-Xiangya. Completed at 1 site in China. Open to female participants aged 40 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Reproductive & Genetic Hospital of CITIC-Xiangya · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing estradiol in Infertility — 2 open to participants now, 2 under way, none of them phase 3. Estradiol · Infertility.
Among the 22 studies testing estradiol in Infertility, this one is the 5th largest by enrollment, is one of 2 that started in 2017, is one of 8 with no phase, and was the 16th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →2 of the 22 studies testing estradiol in Infertility are open now, in 2 countries. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 18–38 · Women only · Healthy volunteers
Mansoura University · Sites in Egypt
Ages 20–38 · Women only
By country, each count listing its studies:
Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 40 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 552 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 155 across the 22 interventional studies. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 10 most frequent:
Reproductive & Genetic Hospital of CITIC-Xiangya is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
12 studies in Infertility by Reproductive & Genetic Hospital of CITIC-Xiangya: 1 open now, 1 under way, none of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 12 studies in Infertility by Reproductive & Genetic Hospital of CITIC-Xiangya, this one is one of 2 that started in 2017, is one of 7 with no phase, and was the 3rd registered.
Reproductive & Genetic Hospital of CITIC-Xiangya’s Infertility studies by the year they started, since 2013.
1 of the studies testing estradiol in Infertility that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06686537University of Colorado, DenverConvergent Mechanisms Underlying Reprometabolic Syndrome in Women | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing estradiol in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Reproductive & Genetic Hospital of CITIC-Xiangya’s 12 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of study is to assess the efficacy of add-on estrogen pretreatment in GnRH antagonist protocol on oocyte retrieval as compared with GnRH antagonist protocol for patients with poor ovarian response Add-on estrogen pretreatment protocol is superior to none pretreatment GnRH antagonist protocol for the number of oocytes retrieval
Women of advanced maternal age seeking ART treatment are characterized as poor ovarian responders in the process of ovarian simulation. Poor response to ovarian stimulation causes high cycle cancellation rate and extremely low pregnancy rate.
More attention has been paid to the potential interest of steroid pretreatments in GnRH antagonist cycles; not only for scheduling the GnRH antagonist cycles, but also for synchronizing the follicular growth which may result in more oocytes retrieved. But available clinical results are controversial.
Previous studies have shown that utilizing the natural negative feedback of the hypothalamus-pituitary-ovary axis induced by estradiol valerate pretreatment effectively prevented inter-cycle increases in follicle-stimulating hormone, improved follicle synchronization, and resulted in a more coordinated follicular development, leading to the recovery of more mature oocytes. However none of the randomized controlled studies compared estradiol valerate pretreatment or not on treatment outcomes, ongoing pregnancy rate, directly on poor response patients using estradiol valerate pretreatment in GnRH antagonist protocol.
Inclusion Criteria:Bologna criteria
At least two of the following three features must be present:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
the pretreatment group underwent a modified treatment protocol with pretreatment with estogen administering during the cycle preceding the IVF/ICSI cycle. daily dose of 4 mg (2 mg twice a day) estradiol valerate was given orally in the middle luteal phase which is confirmed seven days after ovulation monitoring by the ultrasound up to 2 days of the next menstrual cycle.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
Drug: Follitropin Beta;MSD · Drug: Ganirelix · Drug: hCG · Drug: estradiol valerate
In the control groups standard GnRH-antagonist protocol was applied.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
Drug: Follitropin Beta;MSD · Drug: Ganirelix · Drug: hCG
Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
Also known as: Puregon
A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
Also known as: Orgalutran
Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
Also known as: Ovidrel
Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
Also known as: progynova
The number of oocytes retrieved by the IVG 36 hours after hCG administration
The total MII oocytes retrievedd
Time frame: 36 hours after hCG administration
Clinical pregnancy rate
clinical pregnancy, defined as intrauterine pregnancy with a positive heartbeat at 6 weeks of gestation.Clinical pregnancy rate:Number of clinical pregnancies expressed per 100 initiated cycles, aspiration cycles, or embryo transfer cycles. When clinical pregnancy rates are given, the denominator must be specified.
Time frame: 6weeks
ongoing pregnancy rate
ongoing pregnancy defined as an intact pregnancy at 12 weeks of gestation
Time frame: 12weeks
Optimal number of embryo
According to the embryonic developmental rate and morphology, the high quality embryos were defined as the next day (D2) transplanted embryos reached 3 or 4 cells and the third day (D3) transplanted embryos reached 6 to 8 cells with morphological grade 1 or 2
Time frame: 1 week
Plan to share: Undecided
Ran from Nov 2017 to primary completion in Jun 2021, 43 months.
Of 386 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 43 months is above that.
Counting every sponsor, half of 416 studies reached it within 24 months; a quarter within 10 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol
Reproductive & Genetic Hospital of CITIC-Xiangya